163 related articles for article (PubMed ID: 17766014)
1. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses.
Kammer AR; Amacker M; Rasi S; Westerfeld N; Gremion C; Neuhaus D; Zurbriggen R
Vaccine; 2007 Oct; 25(41):7065-74. PubMed ID: 17766014
[TBL] [Abstract][Full Text] [Related]
2. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
Bungener L; Huckriede A; de Mare A; de Vries-Idema J; Wilschut J; Daemen T
Vaccine; 2005 Jan; 23(10):1232-41. PubMed ID: 15652665
[TBL] [Abstract][Full Text] [Related]
3. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
[TBL] [Abstract][Full Text] [Related]
4. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial.
Peduzzi E; Westerfeld N; Zurbriggen R; Pluschke G; Daubenberger CA
Clin Immunol; 2008 May; 127(2):188-97. PubMed ID: 18337175
[TBL] [Abstract][Full Text] [Related]
5. Influenza vaccines: the virosome concept.
Wilschut J
Immunol Lett; 2009 Feb; 122(2):118-21. PubMed ID: 19100779
[TBL] [Abstract][Full Text] [Related]
6. The effect of pre-existing immunity on the capacity of influenza virosomes to induce cytotoxic T lymphocyte activity.
de Mare A; Bungener LB; Regts J; de Vries-Idema J; van der Zee AG; Wilschut J; Daemen T
Vaccine; 2008 May; 26(19):2314-21. PubMed ID: 18400343
[TBL] [Abstract][Full Text] [Related]
7. Peptides delivered by immunostimulating reconstituted influenza virosomes.
Westerfeld N; Zurbriggen R
J Pept Sci; 2005 Nov; 11(11):707-12. PubMed ID: 16059967
[TBL] [Abstract][Full Text] [Related]
8. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
[TBL] [Abstract][Full Text] [Related]
9. Virosomes for antigen and DNA delivery.
Daemen T; de Mare A; Bungener L; de Jonge J; Huckriede A; Wilschut J
Adv Drug Deliv Rev; 2005 Jan; 57(3):451-63. PubMed ID: 15560951
[TBL] [Abstract][Full Text] [Related]
10. The virosome concept for influenza vaccines.
Huckriede A; Bungener L; Stegmann T; Daemen T; Medema J; Palache AM; Wilschut J
Vaccine; 2005 Jul; 23 Suppl 1():S26-38. PubMed ID: 16026906
[TBL] [Abstract][Full Text] [Related]
11. Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage.
de Jonge J; Amorij JP; Hinrichs WL; Wilschut J; Huckriede A; Frijlink HW
Eur J Pharm Sci; 2007 Sep; 32(1):33-44. PubMed ID: 17628452
[TBL] [Abstract][Full Text] [Related]
12. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA.
Shen E; Li L; Li L; Feng L; Lu L; Yao Z; Lin H; Wu C
Cell Mol Immunol; 2007 Apr; 4(2):113-20. PubMed ID: 17484805
[TBL] [Abstract][Full Text] [Related]
13. Influenza virosomes in vaccine development.
Huckriede A; Bungener L; Daemen T; Wilschut J
Methods Enzymol; 2003; 373():74-91. PubMed ID: 14714397
[TBL] [Abstract][Full Text] [Related]
14. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
15. Chimeric virus-like particles for the delivery of an inserted conserved influenza A-specific CTL epitope.
Cheong WS; Reiseger J; Turner SJ; Boyd R; Netter HJ
Antiviral Res; 2009 Feb; 81(2):113-22. PubMed ID: 19007818
[TBL] [Abstract][Full Text] [Related]
16. Influenza virosomes as a vaccine adjuvant and carrier system.
Moser C; Amacker M; Zurbriggen R
Expert Rev Vaccines; 2011 Apr; 10(4):437-46. PubMed ID: 21506642
[TBL] [Abstract][Full Text] [Related]
17. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.
Bessa J; Schmitz N; Hinton HJ; Schwarz K; Jegerlehner A; Bachmann MF
Eur J Immunol; 2008 Jan; 38(1):114-26. PubMed ID: 18081037
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
[TBL] [Abstract][Full Text] [Related]
19. Virosomal adjuvanted antigen delivery systems.
Moser C; Metcalfe IC; Viret JF
Expert Rev Vaccines; 2003 Apr; 2(2):189-96. PubMed ID: 12899570
[TBL] [Abstract][Full Text] [Related]
20. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
Bolhassani A; Zahedifard F; Taghikhani M; Rafati S
Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
